ArticleJournal of cardiovascular translational research2013
Nuclear reprogramming with c-Myc potentiates glycolytic capacity of derived induced pluripotent stem cells.
Article in Journal of cardiovascular translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 54 citations in OpenAlex.
- Proteomic landscape of porcine induced neural stem cell reprogramming and differentiation.PeerJ · 2025Article
- Metabolic Profiles of Cancer Stem Cells and Normal Stem Cells and Their Therapeutic Significance.Cells · 2023Review
- BEX1 supports the stemness of hepatoblastoma by facilitating Warburg effect in a PPARγ/PDK1 dependent manner.British journal of cancer · 2023Article
- Crotonylation of GAPDH regulates human embryonic stem cell endodermal lineage differentiation and metabolic switch.Stem cell research & therapy · 2023Article
- Leucine and Arginine Availability Modulate Mouse Embryonic Stem Cell Proliferation and Metabolism.International journal of molecular sciences · 2022Article
- Testicular germ cell tumors arise in the absence of sex-specific differentiation.Development (Cambridge, England) · 2021Article
- Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2021Article
- Cancer Stem Cells: Metabolic Characterization for Targeted Cancer Therapy.Frontiers in oncology · 2021Review
- Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.Molecules (Basel, Switzerland) · 2020Review
- Energy Metabolism Regulates Stem Cell Pluripotency.Frontiers in cell and developmental biology · 2020Review
- Metabolic-Epigenetic Axis in Pluripotent State Transitions.Epigenomes · 2019Review
- Review
- Article
- MYC Releases Early Reprogrammed Human Cells from Proliferation Pause via Retinoblastoma Protein Inhibition.Cell reports · 2018Article
- Noncoding RNAs in the Regulation of Pluripotency and Reprogramming.Stem cell reviews and reports · 2018Review
- Physiological oxygen culture reveals retention of metabolic memory in human induced pluripotent stem cells.PloS one · 2018Article
- Mitochondrial-epigenetic crosstalk in environmental toxicology.Toxicology · 2017Review
- Metabolic switching and cell fate decisions: implications for pluripotency, reprogramming and development.Current opinion in genetics & development · 2017Review
- Current status in cancer cell reprogramming and its clinical implications.Journal of cancer research and clinical oncology · 2017Review
- Metabolic remodeling during the loss and acquisition of pluripotency.Development (Cambridge, England) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Reprogramming strategies influence the differentiation capacity of derived induced pluripotent stem (iPS) cells. Removal of the reprogramming factor c-Myc reduces tumorigenic incidence and increases cardiogenic potential of iPS cells. c-Myc is a regulator of energy metabolism, yet the impact on metabolic reprogramming underlying pluripotent induction is unknown. Here, mitochondrial and metabolic interrogation of iPS cells derived with (4F) and without (3F) c-Myc demonstrated that nuclear reprogramming consistently reverted mitochondria to embryonic-like immature structures. Metabolomic profiling segregated derived iPS cells from the parental somatic source based on the attained pluripotency-associated glycolytic phenotype and discriminated between 3F versus 4F clones based upon glycolytic intermediates. Real-time flux analysis demonstrated a greater glycolytic capacity in 4F iPS cells, in the setting of equivalent oxidative capacity to 3F iPS cells. Thus, inclusion of c-Myc potentiates the pluripotent glycolytic behavior of derived iPS cells, supporting c-Myc-free reprogramming as a strategy to facilitate oxidative metabolism-dependent lineage engagement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.